Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SciSparc Ltd. - Ordinary Shares (NQ:SPRC)

4.300 -0.170 (-3.80%)
Streaming Delayed Price Updated: 2:31 PM EDT, Sep 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about SciSparc Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
SciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds
Clearmind Medicine submitted patent applications to protect the novel compounds 
From SciSparc Ltd
Via GlobeNewswire
Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds
From Clearmind Medicine Inc.
Via GlobeNewswire
SciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Reached First Milestone for its Future Machine Learning System
From SciSparc Ltd
Via GlobeNewswire
SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Three Provisional Patent Applications in the US
From SciSparc Ltd
Via GlobeNewswire
Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US
From Clearmind Medicine Inc.
Via GlobeNewswire
SciSparc Announces Corporate Restructuring plan
From SciSparc Ltd
Via GlobeNewswire
SciSparc to Investigate and Evaluate Concerns of Illegal Trading of its Ordinary Shares
From SciSparc Ltd
Via GlobeNewswire
SciSparc Receives Approval to Conduct its Clinical Trial in Children with Autism Spectrum Disorder at the Soroka Medical Center
From SciSparc Ltd
Via GlobeNewswire
SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment
From SciSparc Ltd
Via GlobeNewswire
SciSparc Signs Agreement to Conduct its Clinical Trial in Autism Spectrum Disorder with Soroka Medical Center
From SciSparc Ltd
Via GlobeNewswire
SciSparc Ltd. Announces Efficacy of Psychedelic-Based Obesity Treatment of Clearmind Medicine Inc. in Pre-Clinical Trial
From SciSparc Ltd
Via GlobeNewswire
SciSparc Enters Into Non-Binding Letter of Intent to Sell a 50% interest in its Subsidiary that Owns an Amazon Top Seller Brand
From SciSparc Ltd
Via GlobeNewswire
SciSparc Announces Positive Study Results with SCI-210, a Cannabidiol-Based Treatment for Epilepsy
From SciSparc Ltd
Via GlobeNewswire
SciSparc Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
From SciSparc Ltd
Via GlobeNewswire
SciSparc Enters Into Letter of Intent with an E-commerce Company to Establish a Joint Venture to Market and Develop a New Product Line
From SciSparc Ltd
Via GlobeNewswire
SciSparc Gains Competitive Edge with Additional U.S. Patent Granted
From SciSparc Ltd
Via GlobeNewswire
SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s Disease Patients with Agitation
From SciSparc Ltd
Via GlobeNewswire
SciSparc: Wellution™ Signs an Agreement with Logistics Facilities in New Jersey to Supports its Expansion to Additional e-Commerce Platforms
From SciSparc Ltd
Via GlobeNewswire
SciSparc: Wellution™ Successfully Launched a New Keto Gummies Apple Cider Vinegar Product and Generated $100,000 In Revenues Within 30 Days
From SciSparc Ltd
Via GlobeNewswire
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
From SciSparc Ltd
Via GlobeNewswire
SciSparc Completes the Acquisition of Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million
From SciSparc Ltd
Via GlobeNewswire
Traders News Source Interviews Oz Adler Chief Executive Officer at SciSparc Ltd.
NEW YORK, NY / ACCESSWIRE / July 7, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid cap publicly traded companies recently issued a... 
From Traders News Source
Via AccessWire
R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions
Palm Beach, FL – June 29 2022 – FinancialNewsMedia.com News Commentary – In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in the... 
Via FinancialNewsMedia
Central Nervous System (CNS) Therapeutics Global Market Expected to Reach $154 Billion By 2027
Palm Beach, FL – June 9, 2022 – FinancialNewsMedia.com News Commentary – The central nervous system (CNS) consists of the brain and spinal cord and brain and nervous system problems are more common and... 
Via FinancialNewsMedia
Rising Cases Of Mental Health Disorders of Stress, Anxiety & Addiction Fueling Need for Central Nervous System Therapeutics
Palm Beach, FL – June 7, 2022 – FinancialNewsMedia.com News Commentary – The global Central Nervous System (CNS) treatments and its market revenues had been steadily growing pre-pandemic and are still... 
Via FinancialNewsMedia
Aegis Capital Corp. Acted as Exclusive Placement Agent on a $10 Million Private Placement Priced At-the-Market for SciSparc Ltd. (NASDAQ:SPRC).
NEW YORK, NY / ACCESSWIRE / June 2, 2022 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $10 Million Private Placement Priced At-the-Market for SciSparc Ltd. (NASDAQ:SPRC). 
From Aegis Capital Corp.
Via AccessWire
Global Central Nervous System Treatment Market Is Expected to Reach $166 Billion In 2028
Palm Beach, FL – May 26, 2022 – FinancialNewsMedia.com News Commentary – Worldwide, there is a rapid increase in the prevalence and incidence of neurological disorders such as multiple sclerosis,... 
Via FinancialNewsMedia
Global Psychedelics Market Is Expected To Reach $8 Billion By 2029
Palm Beach, FL – May 24, 2022 – FinancialNewsMedia.com News Commentary – The Global psychedelic drugs market has been steadily rising for the past few years and is projected to continue at a faster... 
Via FinancialNewsMedia
SciSparc Has Been Granted The Patent in the United States for its Core Technology, Used to Treat Central Nervous System Disorders.
Via AB Newswire
Topics Intellectual Property
Advances for Tourette Syndrome, Alzheimer’s Disease, Pain Management, Autism Spectrum Disorder and Epilepsy from Proprietary Compounds: SciSparc Ltd. (NASDAQ: SPRC)
Via Get News
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.